Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

BACKGROUND: With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine candidate against COVID-19, containing inactivated severe acute r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yanjun, Zeng, Gang, Pan, Hongxing, Li, Changgui, Hu, Yaling, Chu, Kai, Han, Weixiao, Chen, Zhen, Tang, Rong, Yin, Weidong, Chen, Xin, Hu, Yuansheng, Liu, Xiaoyong, Jiang, Congbing, Li, Jingxin, Yang, Minnan, Song, Yan, Wang, Xiangxi, Gao, Qiang, Zhu, Fengcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832443/
https://www.ncbi.nlm.nih.gov/pubmed/33217362
http://dx.doi.org/10.1016/S1473-3099(20)30843-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832443/
https://www.ncbi.nlm.nih.gov/pubmed/33217362
http://dx.doi.org/10.1016/S1473-3099(20)30843-4

Ejemplares similares